CM369, an anti-chemokine receptor 8 (CCR8) monoclonal antibody, is a potential first-in-class drug co-developed by Nuocheng Jianhua and Connoya, and will be developed as a monotherapy or in combination with other therapies for the treatment of high incidence advanced solid tumors, including lung cancer, gastrointestinal cancer,
The specific mechanism of action of CCR8 makes it a potential tumor immune target
"CCR8 is a specific target for Treg cells at tumor sites, and multiple preclinical studies of CM369 have demonstrated its durable efficacy and excellent safety profile," said Dr.
InnoCare Forward-Looking Statements
This press release contains the disclosure of certain forward-looking statements
Source: Nuocheng Jianhua